Literature DB >> 25873736

CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis.

Li-Shiun Chen1, Rayjean J Hung1, Timothy Baker1, Amy Horton1, Rob Culverhouse1, Nancy Saccone1, Iona Cheng1, Bo Deng1, Younghun Han1, Helen M Hansen1, Janet Horsman1, Claire Kim1, Sharon Lutz1, Albert Rosenberger1, Katja K Aben1, Angeline S Andrew1, Naomi Breslau1, Shen-Chih Chang1, Aida Karina Dieffenbach1, Hendrik Dienemann1, Brittni Frederiksen1, Jiali Han1, Dorothy K Hatsukami1, Eric O Johnson1, Mala Pande1, Margaret R Wrensch1, John McLaughlin1, Vidar Skaug1, Henricus F van der Heijden1, Jason Wampfler1, Angela Wenzlaff1, Penella Woll1, Shanbeh Zienolddiny1, Heike Bickeböller1, Hermann Brenner1, Eric J Duell1, Aage Haugen1, Joachim Heinrich1, John E Hokanson1, David J Hunter1, Lambertus A Kiemeney1, Philip Lazarus1, Loic Le Marchand1, Geoffrey Liu1, Jose Mayordomo1, Angela Risch1, Ann G Schwartz1, Dawn Teare1, Xifeng Wu1, John K Wiencke1, Ping Yang1, Zuo-Feng Zhang1, Margaret R Spitz1, Peter Kraft1, Christopher I Amos1, Laura J Bierut1.   

Abstract

BACKGROUND: Recent meta-analyses show strong evidence of associations among genetic variants in CHRNA5 on chromosome 15q25, smoking quantity, and lung cancer. This meta-analysis tests whether the CHRNA5 variant rs16969968 predicts age of smoking cessation and age of lung cancer diagnosis.
METHODS: Meta-analyses examined associations between rs16969968, age of quitting smoking, and age of lung cancer diagnosis in 24 studies of European ancestry (n = 29 072). In each dataset, we used Cox regression models to evaluate the association between rs16969968 and the two primary phenotypes (age of smoking cessation among ever smokers and age of lung cancer diagnosis among lung cancer case patients) and the secondary phenotype of smoking duration. Heterogeneity across studies was assessed with the Cochran Q test. All statistical tests were two-sided.
RESULTS: The rs16969968 allele (A) was associated with a lower likelihood of smoking cessation (hazard ratio [HR] = 0.95, 95% confidence interval [CI] = 0.91 to 0.98, P = .0042), and the AA genotype was associated with a four-year delay in median age of quitting compared with the GG genotype. Among smokers with lung cancer diagnoses, the rs16969968 genotype (AA) was associated with a four-year earlier median age of diagnosis compared with the low-risk genotype (GG) (HR = 1.08, 95% CI = 1.04 to 1.12, P = 1.1*10(-5)).
CONCLUSION: These data support the clinical significance of the CHRNA5 variant rs16969968. It predicts delayed smoking cessation and an earlier age of lung cancer diagnosis in this meta-analysis. Given the existing evidence that this CHRNA5 variant predicts favorable response to cessation pharmacotherapy, these findings underscore the potential clinical and public health importance of rs16969968 in CHRNA5 in relation to smoking cessation success and lung cancer risk.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25873736      PMCID: PMC4822525          DOI: 10.1093/jnci/djv100

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  36 in total

1.  Biochemical verification of tobacco use and cessation.

Authors: 
Journal:  Nicotine Tob Res       Date:  2002-05       Impact factor: 4.244

2.  Acetylcholine receptor (AChR) α5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (α4β2)₂α5 AChR function.

Authors:  Alexander Kuryatov; Wade Berrettini; Jon Lindstrom
Journal:  Mol Pharmacol       Date:  2010-09-29       Impact factor: 4.436

3.  Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success.

Authors:  Li-Shiun Chen; Timothy B Baker; Megan E Piper; Naomi Breslau; Dale S Cannon; Kimberly F Doheny; Stephanie M Gogarten; Eric O Johnson; Nancy L Saccone; Jen C Wang; Robert B Weiss; Alison M Goate; Laura Jean Bierut
Journal:  Am J Psychiatry       Date:  2012-07       Impact factor: 18.112

4.  CHRNA3 rs1051730 genotype and short-term smoking cessation.

Authors:  Marcus R Munafò; Elaine C Johnstone; Donna Walther; George R Uhl; Michael F G Murphy; Paul Aveyard
Journal:  Nicotine Tob Res       Date:  2011-06-20       Impact factor: 4.244

5.  Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy.

Authors:  Jane E Sarginson; Joel D Killen; Laura C Lazzeroni; Stephen P Fortmann; Heather S Ryan; Alan F Schatzberg; Greer M Murphy
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-01-25       Impact factor: 3.568

6.  Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.

Authors:  Andrew W Bergen; Harold S Javitz; Ruth Krasnow; Denise Nishita; Martha Michel; David V Conti; Jinghua Liu; Won Lee; Christopher K Edlund; Sharon Hall; Pui-Yan Kwok; Neal L Benowitz; Timothy B Baker; Rachel F Tyndale; Caryn Lerman; Gary E Swan
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

7.  21st-century hazards of smoking and benefits of cessation in the United States.

Authors:  Prabhat Jha; Chinthanie Ramasundarahettige; Victoria Landsman; Brian Rostron; Michael Thun; Robert N Anderson; Tim McAfee; Richard Peto
Journal:  N Engl J Med       Date:  2013-01-24       Impact factor: 91.245

8.  Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.

Authors:  David P King; Sara Paciga; Eve Pickering; Neal L Benowitz; Laura J Bierut; David V Conti; Jaakko Kaprio; Caryn Lerman; Peter W Park
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

9.  Increased genetic vulnerability to smoking at CHRNA5 in early-onset smokers.

Authors:  Sarah M Hartz; Susan E Short; Nancy L Saccone; Robert Culverhouse; LiShiun Chen; Tae-Hwi Schwantes-An; Hilary Coon; Younghun Han; Sarah H Stephens; Juzhong Sun; Xiangning Chen; Francesca Ducci; Nicole Dueker; Nora Franceschini; Josef Frank; Frank Geller; Daniel Gubjartsson; Nadia N Hansel; Chenhui Jiang; Kaisu Keskitalo-Vuokko; Zhen Liu; Leo-Pekka Lyytikäinen; Martha Michel; Rajesh Rawal; Albert Rosenberger; Paul Scheet; John R Shaffer; Alexander Teumer; John R Thompson; Jacqueline M Vink; Nicole Vogelzangs; Angela S Wenzlaff; William Wheeler; Xiangjun Xiao; Bao-Zhu Yang; Steven H Aggen; Anthony J Balmforth; Sebastian E Baumeister; Terri Beaty; Siiri Bennett; Andrew W Bergen; Heather A Boyd; Ulla Broms; Harry Campbell; Nilanjan Chatterjee; Jingchun Chen; Yu-Ching Cheng; Sven Cichon; David Couper; Francesco Cucca; Danielle M Dick; Tatiana Foroud; Helena Furberg; Ina Giegling; Fangyi Gu; Alistair S Hall; Jenni Hällfors; Shizhong Han; Annette M Hartmann; Caroline Hayward; Kauko Heikkilä; John K Hewitt; Jouke Jan Hottenga; Majken K Jensen; Pekka Jousilahti; Marika Kaakinen; Steven J Kittner; Bettina Konte; Tellervo Korhonen; Maria-Teresa Landi; Tiina Laatikainen; Mark Leppert; Steven M Levy; Rasika A Mathias; Daniel W McNeil; Sarah E Medland; Grant W Montgomery; Thomas Muley; Tanda Murray; Matthias Nauck; Kari North; Michele Pergadia; Ozren Polasek; Erin M Ramos; Samuli Ripatti; Angela Risch; Ingo Ruczinski; Igor Rudan; Veikko Salomaa; David Schlessinger; Unnur Styrkársdóttir; Antonio Terracciano; Manuela Uda; Gonneke Willemsen; Xifeng Wu; Goncalo Abecasis; Kathleen Barnes; Heike Bickeböller; Eric Boerwinkle; Dorret I Boomsma; Neil Caporaso; Jubao Duan; Howard J Edenberg; Clyde Francks; Pablo V Gejman; Joel Gelernter; Hans Jörgen Grabe; Hyman Hops; Marjo-Riitta Jarvelin; Jorma Viikari; Mika Kähönen; Kenneth S Kendler; Terho Lehtimäki; Douglas F Levinson; Mary L Marazita; Jonathan Marchini; Mads Melbye; Braxton D Mitchell; Jeffrey C Murray; Markus M Nöthen; Brenda W Penninx; Olli Raitakari; Marcella Rietschel; Dan Rujescu; Nilesh J Samani; Alan R Sanders; Ann G Schwartz; Sanjay Shete; Jianxin Shi; Margaret Spitz; Kari Stefansson; Gary E Swan; Thorgeir Thorgeirsson; Henry Völzke; Qingyi Wei; H-Erich Wichmann; Christopher I Amos; Naomi Breslau; Dale S Cannon; Marissa Ehringer; Richard Grucza; Dorothy Hatsukami; Andrew Heath; Eric O Johnson; Jaakko Kaprio; Pamela Madden; Nicholas G Martin; Victoria L Stevens; Jerry A Stitzel; Robert B Weiss; Peter Kraft; Laura J Bierut
Journal:  Arch Gen Psychiatry       Date:  2012-08

10.  Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances.

Authors:  G R Uhl; D Walther; R Musci; C Fisher; J C Anthony; C L Storr; F M Behm; W W Eaton; N Ialongo; J E Rose
Journal:  Mol Psychiatry       Date:  2012-11-06       Impact factor: 15.992

View more
  44 in total

1.  The value of control conditions for evaluating pharmacogenetic effects.

Authors:  Li-Shiun Chen; Timothy B Baker; Laura J Bierut
Journal:  Pharmacogenomics       Date:  2015-11-26       Impact factor: 2.533

Review 2.  Opportunities and Challenges for Environmental Exposure Assessment in Population-Based Studies.

Authors:  Chirag J Patel; Jacqueline Kerr; Duncan C Thomas; Bhramar Mukherjee; Beate Ritz; Nilanjan Chatterjee; Marta Jankowska; Juliette Madan; Margaret R Karagas; Kimberly A McAllister; Leah E Mechanic; M Daniele Fallin; Christine Ladd-Acosta; Ian A Blair; Susan L Teitelbaum; Christopher I Amos
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-07-14       Impact factor: 4.254

3.  Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial.

Authors:  Li-Shiun Chen; Timothy B Baker; J Philip Miller; Michael Bray; Nina Smock; Jingling Chen; Faith Stoneking; Robert C Culverhouse; Nancy L Saccone; Christopher I Amos; Robert M Carney; Douglas E Jorenby; Laura J Bierut
Journal:  Clin Pharmacol Ther       Date:  2020-08-04       Impact factor: 6.875

4.  Genome-Wide Association Study of Heavy Smoking and Daily/Nondaily Smoking in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).

Authors:  Nancy L Saccone; Leslie S Emery; Tamar Sofer; Stephanie M Gogarten; Diane M Becker; Erwin P Bottinger; Li-Shiun Chen; Robert C Culverhouse; Weimin Duan; Dana B Hancock; H Dean Hosgood; Eric O Johnson; Ruth J F Loos; Tin Louie; George Papanicolaou; Krista M Perreira; Erik J Rodriquez; Claudia Schurmann; Adrienne M Stilp; Adam A Szpiro; Gregory A Talavera; Kent D Taylor; James F Thrasher; Lisa R Yanek; Cathy C Laurie; Eliseo J Pérez-Stable; Laura J Bierut; Robert C Kaplan
Journal:  Nicotine Tob Res       Date:  2018-03-06       Impact factor: 4.244

5.  The 2016 Ferno Award Address: Three Things.

Authors:  Timothy B Baker
Journal:  Nicotine Tob Res       Date:  2017-08-01       Impact factor: 4.244

Review 6.  Oral Cell DNA Adducts as Potential Biomarkers for Lung Cancer Susceptibility in Cigarette Smokers.

Authors:  Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2016-12-01       Impact factor: 3.739

Review 7.  Preparing the Way: Exploiting Genomic Medicine to Stop Smoking.

Authors:  Laura J Bierut; Rachel F Tyndale
Journal:  Trends Mol Med       Date:  2018-01-04       Impact factor: 11.951

Review 8.  Toward the implementation of genomic applications for smoking cessation and smoking-related diseases.

Authors:  Alex T Ramsey; Li-Shiun Chen; Sarah M Hartz; Nancy L Saccone; Sherri L Fisher; Enola K Proctor; Laura J Bierut
Journal:  Transl Behav Med       Date:  2018-01-29       Impact factor: 3.046

Review 9.  2018 Langley Award for Basic Research on Nicotine and Tobacco: Bringing Precision Medicine to Smoking Cessation.

Authors:  Laura J Bierut
Journal:  Nicotine Tob Res       Date:  2020-02-06       Impact factor: 4.244

Review 10.  Pathways to precision medicine in smoking cessation treatments.

Authors:  Li-Shiun Chen; Amy Horton; Laura Bierut
Journal:  Neurosci Lett       Date:  2016-05-18       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.